Axitinib for the Management of Metastatic Renal Cell Carcinoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2011-06

AUTHORS

Bernard Escudier, Martin Gore

ABSTRACT

In recent years, targeted agents have changed the treatment landscape for patients with advanced renal cell carcinoma (RCC), greatly improving treatment outcomes. Several targeted agents are now licensed for the treatment of metastatic RCC (mRCC), and a number of new agents are under investigation. Axitinib, a small molecule indazole derivative is an oral, potent multitargeted tyrosine kinase receptor inhibitor, which selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3 at subnanomolar concentrations, in vitro. In various nonclinical models, axitinib has demonstrated in vivo target modulation and antiangiogenesis. In pharmacokinetic studies, axitinib administered orally with food at the proposed regimen of 5 mg twice daily continuous daily dosing, is rapidly absorbed, reaching peak concentrations within 2-6 hours. Axitinib is metabolized primarily in the liver via the cytochrome P450 (CYP) system with less than 1% of the administered drug passing unchanged in the urine. The pharmacokinetics of axitinib do not appear to be altered by coadministered chemotherapies, and antacids do not have a clinically significant effect. However, coadministration with CYP3A4 and 1A2 inducers is contraindicated. In addition, proton pump inhibitors reduce the rate of axitinib absorption. Increased axitinib exposure is associated with higher efficacy indicated by decreased tumor perfusion and volume. In three phase II clinical trials in patients with advanced RCC previously treated with cytokines, chemotherapy or targeted agents, axitinib has demonstrated antitumor activity with a favorable non-cumulative toxicity profile. In one study of Western patients with cytokine-refractory mRCC, an objective response rate (ORR) of 44.2% (95% CI 30.5, 58.7) was achieved. The median time to progression was 15.7 months (95% CI 8.4, 23.4) and the median overall survival (OS) was 29.9 months (95% CI 20.3, not estimable). In the second study of patients with sorafenib-refractory mRCC, ORR was 22.6% (95% CI 12.9, 35.0). The median progression-free survival (PFS) was 7.4 months (95% CI 6.7, 11.0) and a median OS of 13.6 months (95% CI 8.4, 18.8) was achieved. Results from the third study in Japanese patients with cytokine-refractory mRCC reported an ORR of 55% and median PFS of 12.9 months (95% CI 9.8, 15.6). In the three studies, the most common adverse events reported were fatigue, hypertension, hand-foot syndrome (HFS), and gastrointestinal toxicity, which were generally manageable with standard medical intervention. Of note, the incidence of HFS and proteinuria in the Japanese study was higher than that reported in the Western study in cytokine-refractory mRCC patients. An observed association between diastolic blood pressure ≥90 mmHg and increased efficacy suggests potential use as a prognostic biomarker. However, this requires further investigation. Two randomized phase III clinical trials are ongoing to determine the efficacy of axitinib in patients with mRCC in the first- and second-line setting. These results will help to determine the place of axitinib in the mRCC treatment algorithm. More... »

PAGES

113-126

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/11591240-000000000-00000

DOI

http://dx.doi.org/10.2165/11591240-000000000-00000

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1016051119

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21679004


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escudier", 
        "givenName": "Bernard", 
        "id": "sg:person.01304252172.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden Hospital", 
          "id": "https://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Institute of Cancer Research, Royal Marsden Hospital, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gore", 
        "givenName": "Martin", 
        "id": "sg:person.012024134677.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012024134677.17"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-009-1065-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004421187", 
          "https://doi.org/10.1007/s00280-009-1065-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1065-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004421187", 
          "https://doi.org/10.1007/s00280-009-1065-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1065-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004421187", 
          "https://doi.org/10.1007/s00280-009-1065-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.04.192", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004439246"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-07-0193", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005286411"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature07083", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007540186", 
          "https://doi.org/10.1038/nature07083"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa065044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007947936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp489", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008115229"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-010-9511-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008647671", 
          "https://doi.org/10.1007/s10637-010-9511-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-012-1888-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008970843", 
          "https://doi.org/10.1007/s00280-012-1888-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.06.3602", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009129809"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-05-0410", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009402450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ctrv.2010.01.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009666710"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(07)61904-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010511397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.1293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013684571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-04-1443", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014291431"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(07)70285-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014916629"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2011.07.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016524540"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-05-4665", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017608686"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2008-0261", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018411773"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020862106", 
          "https://doi.org/10.1038/nrc2403"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199804303381805", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021411699"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.04.143", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022422344"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.21.7034", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022707753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025111240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026525857"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00345-004-0466-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026746867", 
          "https://doi.org/10.1007/s00345-004-0466-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00345-004-0466-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026746867", 
          "https://doi.org/10.1007/s00345-004-0466-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm0603-669", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031340920", 
          "https://doi.org/10.1038/nm0603-669"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm0603-669", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031340920", 
          "https://doi.org/10.1038/nm0603-669"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1203985", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033156622", 
          "https://doi.org/10.1038/sj.onc.1203985"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1203985", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033156622", 
          "https://doi.org/10.1038/sj.onc.1203985"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.11-7-753", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034242500"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001099900022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037672318", 
          "https://doi.org/10.1007/s001099900022"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa066838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037798278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd001425", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039056771"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1971", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040662289", 
          "https://doi.org/10.1038/nrc1971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1971", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040662289", 
          "https://doi.org/10.1038/nrc1971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-0652", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040763592"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199609193351207", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041427269"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(09)61921-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041519043"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(08)61039-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045744105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/canjclin.55.2.74", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048020321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(05)65640-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048312099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1359-6349(09)70443-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050228925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.9764", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052849919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd001425.pub2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053135144"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.20.1.289", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064202732"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.02.122", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.01.186", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.06.081", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.08.1638", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204361"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1358/dot.2009.45.9.1424750", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1065063887"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074539535", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074593989", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.16.2972", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074684749"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2009.0043", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077919427"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2009.0043", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077919427"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/1396674/dot.2009.45.9.1414786", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077991262"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-06", 
    "datePublishedReg": "2011-06-01", 
    "description": "In recent years, targeted agents have changed the treatment landscape for patients with advanced renal cell carcinoma (RCC), greatly improving treatment outcomes. Several targeted agents are now licensed for the treatment of metastatic RCC (mRCC), and a number of new agents are under investigation. Axitinib, a small molecule indazole derivative is an oral, potent multitargeted tyrosine kinase receptor inhibitor, which selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3 at subnanomolar concentrations, in vitro. In various nonclinical models, axitinib has demonstrated in vivo target modulation and antiangiogenesis. In pharmacokinetic studies, axitinib administered orally with food at the proposed regimen of 5\u2009mg twice daily continuous daily dosing, is rapidly absorbed, reaching peak concentrations within 2-6 hours. Axitinib is metabolized primarily in the liver via the cytochrome P450 (CYP) system with less than 1% of the administered drug passing unchanged in the urine. The pharmacokinetics of axitinib do not appear to be altered by coadministered chemotherapies, and antacids do not have a clinically significant effect. However, coadministration with CYP3A4 and 1A2 inducers is contraindicated. In addition, proton pump inhibitors reduce the rate of axitinib absorption. Increased axitinib exposure is associated with higher efficacy indicated by decreased tumor perfusion and volume. In three phase II clinical trials in patients with advanced RCC previously treated with cytokines, chemotherapy or targeted agents, axitinib has demonstrated antitumor activity with a favorable non-cumulative toxicity profile. In one study of Western patients with cytokine-refractory mRCC, an objective response rate (ORR) of 44.2% (95% CI 30.5, 58.7) was achieved. The median time to progression was 15.7 months (95% CI 8.4, 23.4) and the median overall survival (OS) was 29.9 months (95% CI 20.3, not estimable). In the second study of patients with sorafenib-refractory mRCC, ORR was 22.6% (95% CI 12.9, 35.0). The median progression-free survival (PFS) was 7.4 months (95% CI 6.7, 11.0) and a median OS of 13.6 months (95% CI 8.4, 18.8) was achieved. Results from the third study in Japanese patients with cytokine-refractory mRCC reported an ORR of 55% and median PFS of 12.9 months (95% CI 9.8, 15.6). In the three studies, the most common adverse events reported were fatigue, hypertension, hand-foot syndrome (HFS), and gastrointestinal toxicity, which were generally manageable with standard medical intervention. Of note, the incidence of HFS and proteinuria in the Japanese study was higher than that reported in the Western study in cytokine-refractory mRCC patients. An observed association between diastolic blood pressure \u226590\u2009mmHg and increased efficacy suggests potential use as a prognostic biomarker. However, this requires further investigation. Two randomized phase III clinical trials are ongoing to determine the efficacy of axitinib in patients with mRCC in the first- and second-line setting. These results will help to determine the place of axitinib in the mRCC treatment algorithm.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/11591240-000000000-00000", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1020803", 
        "issn": [
          "1174-5886", 
          "1179-6901"
        ], 
        "name": "Drugs in R&D", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "name": "Axitinib for the Management of Metastatic Renal Cell Carcinoma", 
    "pagination": "113-126", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "4c7b0d9cbd8ab5ff1d13d3f3fda342d4d0be3f27fe5493ff09a92bbf8dba3376"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21679004"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100883647"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/11591240-000000000-00000"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1016051119"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/11591240-000000000-00000", 
      "https://app.dimensions.ai/details/publication/pub.1016051119"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T15:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8663_00000536.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165%2F11591240-000000000-00000"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/11591240-000000000-00000'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/11591240-000000000-00000'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/11591240-000000000-00000'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/11591240-000000000-00000'


 

This table displays all metadata directly associated to this object as RDF triples.

274 TRIPLES      21 PREDICATES      89 URIs      28 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/11591240-000000000-00000 schema:about N288c6b193663418785e487f6c5d6b797
2 N3537354dcbe64a9fa8153bf3baf2ebb4
3 N480db88bf6be4dea9f950f415eb1767c
4 Nb8f0367975644c48ae2e35f9e7c377ad
5 Nbfb20b35469946f8a8b1e927bb65dfa0
6 Nd022d80921844f2bbe1df57dca5bbc7d
7 Ne6538ba4eb1c48a78086ea735f71091a
8 anzsrc-for:11
9 anzsrc-for:1115
10 schema:author N83233969eaef406b9b0732f3a751ed46
11 schema:citation sg:pub.10.1007/s001099900022
12 sg:pub.10.1007/s00280-009-1065-y
13 sg:pub.10.1007/s00280-012-1888-9
14 sg:pub.10.1007/s00345-004-0466-0
15 sg:pub.10.1007/s10637-010-9511-6
16 sg:pub.10.1038/nature07083
17 sg:pub.10.1038/nm0603-669
18 sg:pub.10.1038/nrc1971
19 sg:pub.10.1038/nrc2403
20 sg:pub.10.1038/sj.onc.1203985
21 https://app.dimensions.ai/details/publication/pub.1074539535
22 https://app.dimensions.ai/details/publication/pub.1074593989
23 https://doi.org/10.1002/14651858.cd001425
24 https://doi.org/10.1002/14651858.cd001425.pub2
25 https://doi.org/10.1016/j.ctrv.2010.01.003
26 https://doi.org/10.1016/j.ejca.2011.07.014
27 https://doi.org/10.1016/s0022-5347(05)65640-6
28 https://doi.org/10.1016/s0140-6736(07)61904-7
29 https://doi.org/10.1016/s0140-6736(08)61039-9
30 https://doi.org/10.1016/s0140-6736(09)61921-8
31 https://doi.org/10.1016/s1359-6349(09)70443-4
32 https://doi.org/10.1016/s1470-2045(07)70285-1
33 https://doi.org/10.1056/nejm199609193351207
34 https://doi.org/10.1056/nejm199804303381805
35 https://doi.org/10.1056/nejmoa060655
36 https://doi.org/10.1056/nejmoa065044
37 https://doi.org/10.1056/nejmoa066838
38 https://doi.org/10.1093/annonc/mdp489
39 https://doi.org/10.1093/jnci/92.3.205
40 https://doi.org/10.1158/0008-5472.can-04-1443
41 https://doi.org/10.1158/0008-5472.can-05-4665
42 https://doi.org/10.1158/1078-0432.ccr-08-0652
43 https://doi.org/10.1158/1535-7163.mct-05-0410
44 https://doi.org/10.1158/1535-7163.mct-07-0193
45 https://doi.org/10.1200/jco.20.1.289
46 https://doi.org/10.1200/jco.2000.18.16.2972
47 https://doi.org/10.1200/jco.2003.02.122
48 https://doi.org/10.1200/jco.2005.01.186
49 https://doi.org/10.1200/jco.2005.03.206
50 https://doi.org/10.1200/jco.2005.04.143
51 https://doi.org/10.1200/jco.2005.04.192
52 https://doi.org/10.1200/jco.2005.06.081
53 https://doi.org/10.1200/jco.2006.06.3602
54 https://doi.org/10.1200/jco.2006.08.1638
55 https://doi.org/10.1200/jco.2008.20.1293
56 https://doi.org/10.1200/jco.2008.21.7034
57 https://doi.org/10.1200/jco.2009.23.9764
58 https://doi.org/10.1358/dot.2009.45.9.1424750
59 https://doi.org/10.1634/theoncologist.11-7-753
60 https://doi.org/10.1634/theoncologist.2008-0261
61 https://doi.org/10.3322/canjclin.55.2.74
62 https://doi.org/10.6004/jnccn.2009.0043
63 https://doi.org/1396674/dot.2009.45.9.1414786
64 schema:datePublished 2011-06
65 schema:datePublishedReg 2011-06-01
66 schema:description In recent years, targeted agents have changed the treatment landscape for patients with advanced renal cell carcinoma (RCC), greatly improving treatment outcomes. Several targeted agents are now licensed for the treatment of metastatic RCC (mRCC), and a number of new agents are under investigation. Axitinib, a small molecule indazole derivative is an oral, potent multitargeted tyrosine kinase receptor inhibitor, which selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3 at subnanomolar concentrations, in vitro. In various nonclinical models, axitinib has demonstrated in vivo target modulation and antiangiogenesis. In pharmacokinetic studies, axitinib administered orally with food at the proposed regimen of 5 mg twice daily continuous daily dosing, is rapidly absorbed, reaching peak concentrations within 2-6 hours. Axitinib is metabolized primarily in the liver via the cytochrome P450 (CYP) system with less than 1% of the administered drug passing unchanged in the urine. The pharmacokinetics of axitinib do not appear to be altered by coadministered chemotherapies, and antacids do not have a clinically significant effect. However, coadministration with CYP3A4 and 1A2 inducers is contraindicated. In addition, proton pump inhibitors reduce the rate of axitinib absorption. Increased axitinib exposure is associated with higher efficacy indicated by decreased tumor perfusion and volume. In three phase II clinical trials in patients with advanced RCC previously treated with cytokines, chemotherapy or targeted agents, axitinib has demonstrated antitumor activity with a favorable non-cumulative toxicity profile. In one study of Western patients with cytokine-refractory mRCC, an objective response rate (ORR) of 44.2% (95% CI 30.5, 58.7) was achieved. The median time to progression was 15.7 months (95% CI 8.4, 23.4) and the median overall survival (OS) was 29.9 months (95% CI 20.3, not estimable). In the second study of patients with sorafenib-refractory mRCC, ORR was 22.6% (95% CI 12.9, 35.0). The median progression-free survival (PFS) was 7.4 months (95% CI 6.7, 11.0) and a median OS of 13.6 months (95% CI 8.4, 18.8) was achieved. Results from the third study in Japanese patients with cytokine-refractory mRCC reported an ORR of 55% and median PFS of 12.9 months (95% CI 9.8, 15.6). In the three studies, the most common adverse events reported were fatigue, hypertension, hand-foot syndrome (HFS), and gastrointestinal toxicity, which were generally manageable with standard medical intervention. Of note, the incidence of HFS and proteinuria in the Japanese study was higher than that reported in the Western study in cytokine-refractory mRCC patients. An observed association between diastolic blood pressure ≥90 mmHg and increased efficacy suggests potential use as a prognostic biomarker. However, this requires further investigation. Two randomized phase III clinical trials are ongoing to determine the efficacy of axitinib in patients with mRCC in the first- and second-line setting. These results will help to determine the place of axitinib in the mRCC treatment algorithm.
67 schema:genre research_article
68 schema:inLanguage en
69 schema:isAccessibleForFree true
70 schema:isPartOf N80505c7f3cf84a6dac75b928ac6c3454
71 Nc4debed0933548b189eae78b986c9635
72 sg:journal.1020803
73 schema:name Axitinib for the Management of Metastatic Renal Cell Carcinoma
74 schema:pagination 113-126
75 schema:productId N1e261905a53b4e8eb177bc1873cda138
76 N39d8254ba35748ffabf5ed71041f0500
77 N6f5cce5baa7b4355b59177bf0cabb647
78 Ncdc25f91d0bd48758b8e4bde79de3754
79 Ne2ea2c1e21da464b987206acfcf02215
80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016051119
81 https://doi.org/10.2165/11591240-000000000-00000
82 schema:sdDatePublished 2019-04-10T15:06
83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
84 schema:sdPublisher Nfda7d751cf894084b78c72166608501a
85 schema:url http://link.springer.com/10.2165%2F11591240-000000000-00000
86 sgo:license sg:explorer/license/
87 sgo:sdDataset articles
88 rdf:type schema:ScholarlyArticle
89 N1e261905a53b4e8eb177bc1873cda138 schema:name readcube_id
90 schema:value 4c7b0d9cbd8ab5ff1d13d3f3fda342d4d0be3f27fe5493ff09a92bbf8dba3376
91 rdf:type schema:PropertyValue
92 N2559cbbad3a541f8afef13c3dad8d86f rdf:first sg:person.012024134677.17
93 rdf:rest rdf:nil
94 N288c6b193663418785e487f6c5d6b797 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Carcinoma, Renal Cell
96 rdf:type schema:DefinedTerm
97 N3537354dcbe64a9fa8153bf3baf2ebb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Clinical Trials as Topic
99 rdf:type schema:DefinedTerm
100 N39d8254ba35748ffabf5ed71041f0500 schema:name pubmed_id
101 schema:value 21679004
102 rdf:type schema:PropertyValue
103 N480db88bf6be4dea9f950f415eb1767c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Humans
105 rdf:type schema:DefinedTerm
106 N6f5cce5baa7b4355b59177bf0cabb647 schema:name dimensions_id
107 schema:value pub.1016051119
108 rdf:type schema:PropertyValue
109 N80505c7f3cf84a6dac75b928ac6c3454 schema:volumeNumber 11
110 rdf:type schema:PublicationVolume
111 N83233969eaef406b9b0732f3a751ed46 rdf:first sg:person.01304252172.82
112 rdf:rest N2559cbbad3a541f8afef13c3dad8d86f
113 Nb8f0367975644c48ae2e35f9e7c377ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Imidazoles
115 rdf:type schema:DefinedTerm
116 Nbfb20b35469946f8a8b1e927bb65dfa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Indazoles
118 rdf:type schema:DefinedTerm
119 Nc4debed0933548b189eae78b986c9635 schema:issueNumber 2
120 rdf:type schema:PublicationIssue
121 Ncdc25f91d0bd48758b8e4bde79de3754 schema:name nlm_unique_id
122 schema:value 100883647
123 rdf:type schema:PropertyValue
124 Nd022d80921844f2bbe1df57dca5bbc7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Angiogenesis Inhibitors
126 rdf:type schema:DefinedTerm
127 Ne2ea2c1e21da464b987206acfcf02215 schema:name doi
128 schema:value 10.2165/11591240-000000000-00000
129 rdf:type schema:PropertyValue
130 Ne6538ba4eb1c48a78086ea735f71091a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Animals
132 rdf:type schema:DefinedTerm
133 Nfda7d751cf894084b78c72166608501a schema:name Springer Nature - SN SciGraph project
134 rdf:type schema:Organization
135 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
136 schema:name Medical and Health Sciences
137 rdf:type schema:DefinedTerm
138 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
139 schema:name Pharmacology and Pharmaceutical Sciences
140 rdf:type schema:DefinedTerm
141 sg:journal.1020803 schema:issn 1174-5886
142 1179-6901
143 schema:name Drugs in R&D
144 rdf:type schema:Periodical
145 sg:person.012024134677.17 schema:affiliation https://www.grid.ac/institutes/grid.424926.f
146 schema:familyName Gore
147 schema:givenName Martin
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012024134677.17
149 rdf:type schema:Person
150 sg:person.01304252172.82 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
151 schema:familyName Escudier
152 schema:givenName Bernard
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82
154 rdf:type schema:Person
155 sg:pub.10.1007/s001099900022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037672318
156 https://doi.org/10.1007/s001099900022
157 rdf:type schema:CreativeWork
158 sg:pub.10.1007/s00280-009-1065-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1004421187
159 https://doi.org/10.1007/s00280-009-1065-y
160 rdf:type schema:CreativeWork
161 sg:pub.10.1007/s00280-012-1888-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008970843
162 https://doi.org/10.1007/s00280-012-1888-9
163 rdf:type schema:CreativeWork
164 sg:pub.10.1007/s00345-004-0466-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026746867
165 https://doi.org/10.1007/s00345-004-0466-0
166 rdf:type schema:CreativeWork
167 sg:pub.10.1007/s10637-010-9511-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008647671
168 https://doi.org/10.1007/s10637-010-9511-6
169 rdf:type schema:CreativeWork
170 sg:pub.10.1038/nature07083 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007540186
171 https://doi.org/10.1038/nature07083
172 rdf:type schema:CreativeWork
173 sg:pub.10.1038/nm0603-669 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031340920
174 https://doi.org/10.1038/nm0603-669
175 rdf:type schema:CreativeWork
176 sg:pub.10.1038/nrc1971 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040662289
177 https://doi.org/10.1038/nrc1971
178 rdf:type schema:CreativeWork
179 sg:pub.10.1038/nrc2403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020862106
180 https://doi.org/10.1038/nrc2403
181 rdf:type schema:CreativeWork
182 sg:pub.10.1038/sj.onc.1203985 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033156622
183 https://doi.org/10.1038/sj.onc.1203985
184 rdf:type schema:CreativeWork
185 https://app.dimensions.ai/details/publication/pub.1074539535 schema:CreativeWork
186 https://app.dimensions.ai/details/publication/pub.1074593989 schema:CreativeWork
187 https://doi.org/10.1002/14651858.cd001425 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039056771
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1002/14651858.cd001425.pub2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053135144
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/j.ctrv.2010.01.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009666710
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/j.ejca.2011.07.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016524540
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/s0022-5347(05)65640-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048312099
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1016/s0140-6736(07)61904-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010511397
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1016/s0140-6736(08)61039-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045744105
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1016/s0140-6736(09)61921-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041519043
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/s1359-6349(09)70443-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050228925
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/s1470-2045(07)70285-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014916629
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1056/nejm199609193351207 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041427269
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1056/nejm199804303381805 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021411699
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1056/nejmoa060655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025111240
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1056/nejmoa065044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007947936
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1056/nejmoa066838 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037798278
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1093/annonc/mdp489 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008115229
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1158/0008-5472.can-04-1443 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014291431
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1158/0008-5472.can-05-4665 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017608686
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1158/1078-0432.ccr-08-0652 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040763592
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1158/1535-7163.mct-05-0410 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009402450
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1158/1535-7163.mct-07-0193 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005286411
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1200/jco.20.1.289 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064202732
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1200/jco.2000.18.16.2972 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074684749
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1200/jco.2003.02.122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203409
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1200/jco.2005.01.186 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204187
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1200/jco.2005.03.206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026525857
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1200/jco.2005.04.143 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022422344
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1200/jco.2005.04.192 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004439246
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1200/jco.2005.06.081 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204278
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1200/jco.2006.06.3602 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009129809
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1200/jco.2006.08.1638 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204361
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1200/jco.2008.20.1293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013684571
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1200/jco.2008.21.7034 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022707753
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1200/jco.2009.23.9764 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052849919
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1358/dot.2009.45.9.1424750 schema:sameAs https://app.dimensions.ai/details/publication/pub.1065063887
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1634/theoncologist.11-7-753 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034242500
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1634/theoncologist.2008-0261 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018411773
262 rdf:type schema:CreativeWork
263 https://doi.org/10.3322/canjclin.55.2.74 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048020321
264 rdf:type schema:CreativeWork
265 https://doi.org/10.6004/jnccn.2009.0043 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077919427
266 rdf:type schema:CreativeWork
267 https://doi.org/1396674/dot.2009.45.9.1414786 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077991262
268 rdf:type schema:CreativeWork
269 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
270 schema:name Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France
271 rdf:type schema:Organization
272 https://www.grid.ac/institutes/grid.424926.f schema:alternateName Royal Marsden Hospital
273 schema:name Institute of Cancer Research, Royal Marsden Hospital, London, UK
274 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...